CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026

Loading news article.

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026 | WAPE

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026

Article summary

Related companies

Comments —